Literature DB >> 19758829

Association of Stenotrophomonas maltophilia infection with lower airway disease in the horse: a retrospective case series.

Lotte Winther1, Rikke Munk Andersen, Keith E Baptiste, Bent Aalbæk, Luca Guardabassi.   

Abstract

Stenotrophomonas maltophilia is being reported with increasing frequency as a human nosocomial pathogen, especially among immuno-compromised patients. To the authors' knowledge, this pathogen has not previously been associated with lower airway disease in the horse. In this paper the clinical findings, laboratory diagnosis and response to treatment of seven cases of respiratory infection with S. maltophilia in horses, presented at three equine referral hospitals in Denmark in 2007, are described. In all cases there was a clinical history of chronic coughing and abundant mucopurulent exudate was observed in the lower trachea on endoscopy. On culture of tracheal aspirate, grey, slow-growing colonies, identified as S. maltophilia by both API 20NE identification and 16s ribosomal DNA sequencing, were identified. All isolates had a similar antibiotic susceptibility pattern characterised by resistance to all penicillins and cephalosporins, and to imipenem, gentamicin, amikacin and rifampicin. Ribotyping and pulsed-field gel electrophoresis of the S. maltophilia isolates from different patients indicated that they were either indistinguishable or closely related. This study indicates that S. maltophilia can be associated with chronic lower airway disease in the horse and provides useful initial insights into the diagnosis, therapy and epidemiology of this novel condition.
Copyright © 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758829     DOI: 10.1016/j.tvjl.2009.08.026

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  8 in total

1.  Characterization of maltocin P28, a novel phage tail-like bacteriocin from Stenotrophomonas maltophilia.

Authors:  Jian Liu; Peng Chen; Congyi Zheng; Yu-Ping Huang
Journal:  Appl Environ Microbiol       Date:  2013-07-08       Impact factor: 4.792

Review 2.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

3.  Are animals a source of Stenotrophomonas maltophilia in human infections? Contributions of a nationwide molecular study.

Authors:  Aurélie Jayol; Camille Corlouer; Marisa Haenni; Mélanie Darty; Karine Maillard; Marine Desroches; Brigitte Lamy; Estelle Jumas-Bilak; Jean-Yves Madec; Jean-Winoc Decousser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-27       Impact factor: 3.267

4.  Genetic Manipulation of Stenotrophomonas maltophilia.

Authors:  Elliott Welker; Yayra Domfeh; Deepti Tyagi; Sanjivni Sinha; Nathan Fisher
Journal:  Curr Protoc Microbiol       Date:  2015-05-01

5.  Rapid identification of Stenotrophomonas maltophilia by peptide nucleic acid fluorescence in situ hybridization.

Authors:  N Hansen; A K I Rasmussen; M J Fiandaca; K N Kragh; T Bjarnsholt; N Høiby; H Stender; L Guardabassi
Journal:  New Microbes New Infect       Date:  2014-03-25

6.  Survival and growth of Stenotrophomonas maltophilia in free-living amoebae (FLA) and bacterial virulence properties.

Authors:  Elodie Denet; Valentin Vasselon; Béatrice Burdin; Sylvie Nazaret; Sabine Favre-Bonté
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

7.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

8.  The haybiome: Characterising the viable bacterial community profile of four different hays for horses following different pre-feeding regimens.

Authors:  Simon Daniels; Jacob Hepworth; Meriel Moore-Colyer
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.